Slide1: ﴀ ﴀ 1.01 The number of active substances with a Norwegian marketing authorisation


Slide2: 1.02 New and withdrawn active ingredients


Slide3: 1.03 Number of medicines in Norway


Slide4: 1.04 The number of marketing authorisations in Norway


Slide5: 1.05 Pharmaceutical sales in Norway in the last few years, 2006-currency


Slide6: 1.06 Pharmaceutical sales in Norway historically


Slide7: 1.07 Percentual annual growth in medicine sales


Slide8: 1.08 Pharmaceutical sales per inhabitant in Norway the last few years


Slide9: 1.09 Pharmaceutical sales per inhabitant historically


Slide10: 1.10 Sales growth by volume


Slide11: 1.11 The Norwegian pharmaceutical market by main therapeutic groups (ATC)


Slide12: 1.12 The top 25 pharmaceutical companies on the Norwegian market


Slide13: 1.13 The top 25 medicines on the Norwegian market in terms of sales value


Slide14: 1.14 The 25 most sold medicines in terms of defined daily doses (DDD)


Slide15: 1.15 The top 25 active ingredients in terms of sales value


Slide16: 1.16 The top 25 active ingredients as measured by defined daily doses (DDD)


Slide17: 1.17 Total sales by distribution chain


Slide18: 1.18 New innovative medicines´ share of total medicine sales


Slide19: 1.19 Sales of new innovative medicines by medicine group


Slide20: 1.20 Sales of generics, DDD


Slide21: 1.21 Generics´ share of the generics interchangeable market


Slide22: 1.22 Sales of parallel imported medicines


Slide23: ﴀ ﴀ 1.23 Market share for Wholesalers


Slide24: 1.24 Pharmacy chain affiliation


Slide25: 1.25 Pharmacy chain market share


Slide26: 1.26 Pharmacy chain market share, excl. hospital pharmacies


Slide27: 2.01 Changes in medicine prices and the general rate of inflation


Slide28: 2.02 Public spending on reimbursable prescription medicines


Slide29: 2.03 Payment for pharmaceutical consumption


Slide30: 2.04 Public spending on medicines per inhabitant


Slide31: 2.06 Public spending on health care and medicines


Slide32: 2.07 Public spending on medicines as a percentage of public health expenditure


Slide33: 2.08 Expenditure on medicines in the private and public sector


Slide34: 2.09 Daily costs for consumption of medicines


Slide35: ﴀ ﴀ 2.11 Pharmaceutical expenditure as share of the total expenditure in healthcare institutions in Norway


Slide36: 2.12 National Insurance expenditure


Slide37: 2.13 Expenditure on health care


Slide38: 3.01 Non-prescription medicines, share of total market value (PRP)


Slide39: 3.02 Non-prescription medicines, share of total market (DDD)


Slide40: 3.03 The top 25 non-prescription medicines in terms of sales value


Slide41: 3.04 Non-prescription medicines sales by selected therapy groups (ATC)


Slide42: 3.05 The top 10 pharmaceutical companies in the non-prescription medicines market


Slide43: 3.06 The top 10 pharmaceutical companies in terms of OTC share of total sales0


Slide44: ﴀ ﴀ 3.07 Sales of non-prescription medicines


Slide45: 3.08 Sales of non-prescription medicines DDDs


Slide46: 3.09 Non-prescription medicines, market share (PRP) in selected countries


Slide47: 3.10 Number of general sales outlets for non-prescription medicines outside pharmacies by trade


Slide48: 3.11 OTC market shares (DDD) – Pharmacies vs general sales outlets


Slide49: 4.01 The top 10 veterinary medicines for aquaculture in terms of sales value


Slide50: 4.02 The top 10 veterinary medicines for mammals in terms of sales value


Slide51: ﴀ ﴀ 4.03 The top 5 companies within aquaculture


Slide52: 4.04 The top 10 companies within veterinary medicine excluding aquaculture


Slide53: 4.05 Sales veterinary antibacterial medicinal products


Slide54: 4.06 Fish farming and use of antibiotics


Slide55: 4.07 Distribution of sales in the market for medicines for mammals


Slide56: 5.01 The pharmaceutical industry's investments in research and development


Slide57: 5.02 Investments in R&D, percentage of sales


Slide58: 5.03 Submitted clinical trials


Slide59: 5.04 Number of ongoing clinical trials within the pharmaceutical industry


Slide60: 5.05 Number of patients in clinical studies


Slide61: ﴀ ﴀ 5.06 Industry initiated clinical trials


Slide62: 5.07 Norway's imports and exports of medicines


Slide63: 5.08 Number of countries receiving pharmaceuticals produced in Norway


Slide64: 5.09 Number of employees in the pharmaceutical industry in Norway


Slide65: 5.10 Employees in pharmaceutical companies with production plants in Norway


Slide66: 6.01 International price index for medicines


Slide67: 6.02 Leading pharmaceutical companies on the global market


Slide68: 6.03 Mergers and acquisitions


Slide69: 6.04 Leading pharmaceuticals on the global market


Slide70: 6.05 The Norwegian medicines market in relation to Europe


Slide71: 6.06 Pharmaceutical consumption (DDD) in the Nordic countries pr inhabitant


Slide72: 6.07 Medicines sales (PPP) per inhabitant in the Nordic Countries


Slide73: 6.08 Sales evolution for medicines in the Nordic Countries


Slide74: 6.09 Spending on health care and pharmaceuticals in the OECD


Slide75: 6.10 Spending on medicines as share of spending on health care in the OECD


Slide76: 6.11 Public spending on medicines as a percentage of public health care expenditure in the OECD


Slide77: 6.12 Raesearch and development costs for new medicines


Slide78: 6.13 Percentage of medicines stopped at each stage of development


Slide79: 6.14 Total number of new active substances introduced worldwide


Slide80: 6.15 The pharmaceutical industry's investments in research and development in Europe


Slide81: 6.16 Total R&D investements divided into biotech and other medicines


Slide82: 6.17 The pharmaceutical industry's R&D investments in Europa and the U.S


Slide83: 6.18 Allocation of R&D investments by category


Slide84: 6.19 R&D expenses biotechnology divided by region


Slide85: 6.20 Distribution of global pharmaceutical sales by region


Slide86: 6.21 Global sales growth medicines


Slide87: 6.22 Pharmaceutical expenditure as share of health expenditure in Europe


Slide88: 6.23 Copayment for reimbursable medicines


Slide89: 6.24 VAT on medicines and other goods and services in Europe


Slide90: 6.25 Generics share of total market


Slide91: 6.26 Number of inhabitants per pharmacy in Europe


Slide92: 6.27 Distribution of medicine sales in the Nordic countries


Slide93: 6.28 R&D investments as a percentage of Gross Domestic Product


Slide94: 7.01 Medicine sales by county


Slide95: 7.02 Inhabitants per physician in the counties


Slide96: 7.03 Finnmark


Slide97: 7.04 Troms


Slide98: 7.05 Nordland


Slide99: 7.06 Nord-Trøndelag


Slide100: 7.07 Sør-Trøndelag


Slide101: 7.08 Møre og Romsdal


Slide102: 7.09 Sogn og Fjordane


Slide103: 7.10 Hordaland


Slide104: 7.11 Rogaland


Slide105: 7.13 Aust-Agder


Slide106: 7.14 Telemark


Slide107: 7.15 Vestfold


Slide108: 7.16 Buskerud


Slide109: 7.17 Akershus


Slide110: 7.18 Oslo


Slide111: 7.19 Oppland


Slide112: 7.20 Hedmark


Slide113: 7.21 Østfold